REMS
171 results
1 - 100- REMS
- Overview of Risk Evaluation and Mitigation Systems (REMS)
- ISOtretinoin
- tolvaptan
- thalidomide
- pomalidomide
- vigabatrin
- macitentan
- brodalumab
- pegvaliase
- bosentan
- metreleptin
- inotersen
- teclistamab
- eculizumab
- flibanserin
- duvelisib
- miFEPRIStone
- denosumab
- cloZAPine
- vandetanib
- lomitapide
- ravulizumab
- Risk Evaluation and Mitigation Strategy
- ambrisentan
- alvimopan
- alosetron
- teduglutide
- riociguat
- loxapine
- esketamine
- sodium oxybate
- lenalidomide
- natalizumab
- brexanolone
- OLANZapine
- collagenase clostridium histolyticum
- phentermine/topiramate
- testosterone topical gel
- equivalent
- buprenorphine/naloxone
- mycophenolate mofetil
- elotuzumab
- dose
- panobinostat
- pexidartinib
- melphalan
- alemtuzumab
- peginesatide
- daclizumab
- hydroxyurea
- ezogabine
- mipomersen
- parathyroid hormone
- butorphanol
- fentaNYL (transdermal)
- levorphanol
- albiglutide
- meperidine
- oxyMORphone
- SUFentanil
- buprenorphine
- HYDROmorphone
- methadone
- tapentadol
- FENTANYL (transmucosal)
- codeine
- oxyCODONE
- How to Use Davis's Drug Guide For Nurses
- fentanyl iontophoretic transdermal system
- morphine
- traMADol
- HYDROcodone